Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLUSTOID Wiesenlieschgras
- Development stage
- Phase 2
- Lead developer
- Inmunotek
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
CLUSTOID Wiesenlieschgras is a subcutaneous cluster immunotherapy (SCIT) biological product consisting of a glutaraldehyde-polymerized (allergoid) allergen extract. It contains a standardized mixture of six grass pollens (*Holcus lanatus*, *Dactylis glomerata*, *Lolium perenne*, *Phleum pratense*, *Poa pratensis*, *Festuca elatior*) and rye (*Secale cereale*), adsorbed onto aluminum hydroxide. Developed by INMUNOTEK and marketed in Germany by ROXALL Medizin, it is indicated for the treatment of IgE-mediated allergic rhinitis and allergic rhinoconjunctivitis (with or without mild-to-moderate seasonal allergic asthma) in patients sensitized to grass and/or rye pollen. The cluster protocol allows for a faster updosing phase compared to conventional immunotherapy, typically reaching the maintenance dose in a shorter timeframe.
- Brand names
- CLUSTOIDCLUSTEKALXOID
- Other names
- WiesenlieschgrasTimothy grass allergoid mixture
02
Targets
BCR (Immunoglobulin G B Cell Receptor)MHC class II-restricted CD4+ T-cell receptor (grass pollen-specific)IgE (Immunoglobulin E)
Beyond the preview
Go deeper on CLUSTOID Wiesenlieschgras.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLUSTOID Wiesenlieschgras.